Treatment for Psoriasis with Concurrent Fungal Infection
For a patient with psoriasis and a concurrent fungal infection, you must first treat the fungal infection with appropriate antifungal therapy before initiating or continuing immunosuppressive psoriasis treatments, and avoid certain medications that can worsen both conditions.
Critical Drug Avoidance
Immediately discontinue or avoid chloroquine and mepacrine, as these antimalarials are associated with severe, even life-threatening deterioration of psoriasis 1. This is particularly relevant since these agents might be considered for certain infections but are absolutely contraindicated in psoriasis patients.
Management Algorithm
Step 1: Identify and Treat the Fungal Infection
The type of fungal infection determines your antifungal choice:
For superficial fungal infections (dermatophytosis/tinea):
- Terbinafine is superior to fluconazole for onychomycosis in psoriasis patients, showing clinical improvement in 70.8% versus 40.7% of cases (p=0.002) 2
- Discontinue methotrexate and topical corticosteroids during active dermatophyte infection, as these immunosuppressants exacerbate fungal infections 3
- Resume psoriasis treatment only after fungal infection is controlled 3
For Candida colonization/infection:
- Use fluconazole 400 mg daily or voriconazole for resistant cases 4
- Treat for 2 weeks after clearance of infection 4
For severe/systemic fungal infections:
- Use lipid formulation amphotericin B (3-5 mg/kg daily) for initial therapy 5
- Step down to itraconazole 200 mg twice daily after clinical response 5
- Monitor itraconazole serum levels after 2 weeks to ensure adequate drug exposure 5
Step 2: Select Appropriate Psoriasis Treatment
Once the fungal infection is controlled or during concurrent management:
Topical therapy for mild-moderate psoriasis:
- Coal tar (0.5-10% crude coal tar in petroleum jelly) - extremely safe option 1
- Dithranol 0.1-0.25% (increase as tolerated) 1
- Topical corticosteroids: Use only moderately potent preparations (≤100g/month), with regular review and periods of alternative treatment 1
Systemic therapy for severe psoriasis:
The choice depends on infection risk profile:
IL-17 inhibitors (secukinumab, ixekizumab) carry the HIGHEST risk of fungal infections, particularly candidiasis 6. However, when combined with traditional Chinese medicine approaches, secukinumab showed reduced fungal infection rates (12.5% vs 30.6% with monotherapy) 7
IL-23 inhibitors (guselkumab, risankizumab) have LOWER fungal infection risk compared to IL-17 inhibitors and should be preferred in patients with fungal infection history 6, 8
TNF inhibitors have INTERMEDIATE fungal infection risk - higher than IL-23 inhibitors but may be acceptable with close monitoring 6, 8
Apremilast is particularly beneficial as it not only treats psoriasis but also reduces fungal colonization burden, achieving 83% clearance of single-species Candida colonization and 78% resolution of onychomycosis at 52 weeks 9
Methotrexate should be avoided or used with extreme caution during active fungal infections due to immunosuppression exacerbating fungal growth 3
Cyclosporin requires careful consideration - while effective for psoriasis, it increases infection risk through immunosuppression 10
Step 3: Risk Factor Management
Address these independent risk factors for fungal infection:
- Age (older patients have higher risk) 6
- Diabetes mellitus (odds ratio 2.40) - optimize glycemic control 6
- Avoid beta-blockers and NSAIDs when possible, as they may worsen psoriasis 1
Monitoring Protocol
- Perform mycological testing (dermoscopy, culture, histopathology) before starting immunosuppressive therapy 3
- Monitor for new fungal infections every 3 months during biologic therapy 7
- Check for oral candidiasis, onychomycosis, and skin dermatophytosis at each visit 2, 9
- No psoriasis flare-ups were attributed to systemic antifungal treatment in clinical studies 2
Key Clinical Pitfalls
Do not assume all annular lesions are psoriasis - dermatophytosis can closely mimic psoriatic plaques. Always perform mycological testing when lesions appear atypical or fail to respond to standard psoriasis therapy 3.
Do not continue topical corticosteroids if fungal infection is suspected, as this creates a diagnostic and therapeutic trap where the steroid temporarily improves inflammation while allowing fungal proliferation 3.
Patients requiring systemic immunosuppression should be under dermatologist supervision due to the complexity of managing concurrent infections 1.